Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
IMUC's Cash to Debt is ranked higher than
90% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. IMUC: No Debt )
IMUC' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
IMUC's Interest Coverage is ranked higher than
89% of the 582 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IMUC: No Debt )
IMUC' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 2
Z-Score: 10.83
M-Score: -2.30
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -28.92
IMUC's ROE (%) is ranked higher than
76% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. IMUC: -28.92 )
IMUC' s 10-Year ROE (%) Range
Min: -4907.62   Max: -35.53
Current: -28.92

-4907.62
-35.53
ROA (%) -25.91
IMUC's ROA (%) is ranked higher than
74% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. IMUC: -25.91 )
IMUC' s 10-Year ROA (%) Range
Min: -417.42   Max: -31.45
Current: -25.91

-417.42
-31.45
ROC (Joel Greenblatt) (%) -16774.83
IMUC's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. IMUC: -16774.83 )
IMUC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -79400   Max: -13323.94
Current: -16774.83

-79400
-13323.94
EBITDA Growth (3Y)(%) -16.00
IMUC's EBITDA Growth (3Y)(%) is ranked higher than
68% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. IMUC: -16.00 )
IMUC' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -32.2   Max: 102.7
Current: -16

-32.2
102.7
EPS Growth (3Y)(%) -28.10
IMUC's EPS Growth (3Y)(%) is ranked higher than
63% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. IMUC: -28.10 )
IMUC' s 10-Year EPS Growth (3Y)(%) Range
Min: -28.1   Max: 81.7
Current: -28.1

-28.1
81.7
» IMUC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

IMUC Guru Trades in Q4 2013

Paul Tudor Jones 66,303 sh (New)
» More
Q1 2014

IMUC Guru Trades in Q1 2014

Paul Tudor Jones 40,569 sh (-38.81%)
» More
Q2 2014

IMUC Guru Trades in Q2 2014

Paul Tudor Jones 40,569 sh (unchged)
» More
Q3 2014

IMUC Guru Trades in Q3 2014

Paul Tudor Jones 50,124 sh (+23.55%)
» More
» Details

Insider Trades

Latest Guru Trades with IMUC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.85
IMUC's P/B is ranked higher than
91% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. IMUC: 1.85 )
IMUC' s 10-Year P/B Range
Min: 2.72   Max: 17.42
Current: 1.85

2.72
17.42
EV-to-EBIT -2.13
IMUC's EV-to-EBIT is ranked higher than
73% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. IMUC: -2.13 )
IMUC' s 10-Year EV-to-EBIT Range
Min: -19.2   Max: -1.1
Current: -2.13

-19.2
-1.1
Current Ratio 19.83
IMUC's Current Ratio is ranked higher than
95% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. IMUC: 19.83 )
IMUC' s 10-Year Current Ratio Range
Min: 2.64   Max: 76.13
Current: 19.83

2.64
76.13
Quick Ratio 19.83
IMUC's Quick Ratio is ranked higher than
95% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. IMUC: 19.83 )
IMUC' s 10-Year Quick Ratio Range
Min: 2.64   Max: 76.13
Current: 19.83

2.64
76.13

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.00
IMUC's Price/Net Cash is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 53.79 vs. IMUC: 2.00 )
IMUC' s 10-Year Price/Net Cash Range
Min: 1   Max: 93.75
Current: 2

1
93.75
Price/Net Current Asset Value 2.00
IMUC's Price/Net Current Asset Value is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 31.40 vs. IMUC: 2.00 )
IMUC' s 10-Year Price/Net Current Asset Value Range
Min: 1   Max: 93.75
Current: 2

1
93.75
Price/Tangible Book 1.84
IMUC's Price/Tangible Book is ranked higher than
93% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. IMUC: 1.84 )
IMUC' s 10-Year Price/Tangible Book Range
Min: 0.96   Max: 77
Current: 1.84

0.96
77
Earnings Yield (Greenblatt) -46.90
IMUC's Earnings Yield (Greenblatt) is ranked higher than
52% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. IMUC: -46.90 )
IMUC' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -46.9

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:KOL.Germany,
ImmunoCellular Therapeutics Limited was incorporated with the Secretary of State of Delaware on March 20, 1987 under the name Redwing Capital Corp. On November 2, 2006, it amended its Certificate of InCorporation to change its name to ImmunoCellular Therapeutics, Ltd. The Company is a clinical-stage biotechnology company developing immune-based therapies for the treatment of cancers, such as brain and ovarian. Immunotherapy is an approach to treating cancer in which a patient's own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company's product candidate portfolio includes; ICT-107, ICT-121, and ICT-140. The ICT-107 is a DC-based vaccine targeting CSCs and cancer antigens that targets six different tumor-associated antigens that are found on patients' tumor cells; at least four of the six antigens are highly expressed on CSCs. The therapeutic vaccine is used subsequent to conventional therapy or concomitantly with chemotherapy in patients with newly diagnosed GBM. On February 2014, ICT-107 was granted Orphan Drug status by the European Medicines Agency. The ICT-121 is a DC-based vaccine targeting CD133+ CSCs marker that is overexpressed in a wide variety of solid tumors, including ovarian, pancreatic, and breast cancers. The ICT-140 is a DC-based vaccine targeting CSCs and cancer antigens and targets seven different ovarian cancer antigens. Ovarian cancer usually spreads via local shedding into the peritoneal cavity followed by implantation on the peritoneum and via local invasion of bowel and bladder. The Company faces competition from the companies that have significantly more experience in undertaking preclinical testing and human clinical trials with new or improved therapeutic products and obtaining regulatory approvals of such products. The United States and other developed countries regulate the preclinical and clinical testing, manufacturing, labeling, storage, record-keeping, advertising, promotion, export, marketing and distribution of drugs and biologic products. The United States Food and Drug Administration, under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act and other federal statutes and regulations, regulate pharmaceutical and biologic products.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK